The Role of Matrix Metalloproteinase-2 in Vitiligo Treatment

被引:0
|
作者
Celik, Heybet Ozkaya [1 ]
Yilmazer, Demet [2 ]
Atacan, Damla [1 ]
Eskioglu, Fatma [1 ]
Alper, Murat [2 ]
机构
[1] Diskapi Yildirim Beyazit Egitim & Arastirma Hasta, Deri & Zuhrevi Hastaliklari Klin, Ankara, Turkey
[2] Diskapi Yildirim Beyazit Egitim & Arastirma Hasta, Patol Klin, Ankara, Turkey
关键词
Vitiligo; narrowband UVB; MMP-2; IN-VITRO; ULTRAVIOLET; PROGRESSION; EXPRESSION; MIGRATION; THERAPY;
D O I
10.4274/turkderm.44.216
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Design: Vitiligo is an acquired hypomelanotic disorder characterized by circumscribed depigmented macules in the skin resulting from the loss of functional melanocytes. Narrowband-ultraviolet B (NB-UVB)has been used in vitiligo treatment. Possible mechanisms by which NB-UVB induces repigmentation in vitiligo are: regulation of the immune response, melanocyte proliferation and melanocyte migration. In melanocyte migration, the efficacy of NB-UVB might derive from induction of metalloproteinase-2 (MMP-2). In our study, we aimed to test whether there would be an increase in MMP-2 levels by NB-UVB treatment. Material and Method: Twenty-three adult vitiligo patients without any systemic disease and who have not received treatment previously were included in this study. The patients were treated with NB-UVB irradiation. Biopsy specimens taken from all patients before and after the treatment were compared in terms of MMP-2 immunoreactivity. Results: There were statistically significant differences in MMP-2 immunostaining between the tissue specimens taken before and after the treatment. Conclusion: Our study results suggest that the NB-UVB therapy can increase the MMP-2 activity, and MMP-2 may have an important role in vitiligo repigmentation process. (Turkderm 2010; 44: 216-9)
引用
收藏
页码:216 / 219
页数:4
相关论文
共 50 条
  • [41] Neutrophil activator of matrix metalloproteinase-2 (NAM)
    Rollo, Ellen E.
    Hymowitz, Michelle
    Schmidt, Cathleen E.
    Montana, Steve
    Foda, Hussein
    Zucker, Stanley
    CLINICAL & EXPERIMENTAL METASTASIS, 2006, 23 (5-6) : 259 - 268
  • [42] Evaluation of matrix metalloproteinase-2 in lung cancer
    Ali-Labib, Randa
    Louka, Manal Louis
    Galal, Iman Hassan El-Sayed
    Tarek, Marwa
    PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (3-4) : 251 - 257
  • [43] Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview
    Adhikari, Nilanjan
    Mukherjee, Avinaba
    Saha, Achintya
    Jha, Tarun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 129 : 72 - 109
  • [44] Matrix metalloproteinase-2 promoter variability in psoriasis
    Vladimir Vasku
    Julie Bienertova Vasku
    Veronika Slonková
    Kateřina Kaňková
    Anna Vasku
    Archives of Dermatological Research, 2009, 301 : 467 - 473
  • [45] Matrix metalloproteinase-2 and mesangiolysis in diabetic nephropathy
    Kanauchi, M
    Nishioka, H
    Kawano, T
    Uyama, H
    Shiiki, H
    Dohi, K
    NEPHRON, 1999, 83 (02): : 174 - 175
  • [46] Matrix metalloproteinase-2: Not (just) a "hero" of the past
    Henriet, Patrick
    Emonard, Herve
    BIOCHIMIE, 2019, 166 : 223 - 232
  • [47] Inhibition of matrix metalloproteinase-2 by PARP inhibitors
    Nicolescu, Adrian C.
    Holt, Andrew
    Kandasamy, Arulmozhi D.
    Pacher, Pal
    Schulz, Richard
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 387 (04) : 646 - 650
  • [48] Ceruloplasmin binds and inactivates matrix metalloproteinase-2
    Thompson, Michael W.
    FASEB JOURNAL, 2012, 26
  • [49] Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection
    Bencsik, Peter
    Kupai, Krisztina
    Goerbe, Aniko
    Kenyeres, Eva
    Varga, Zoltan V.
    Paloczi, Janos
    Gaspar, Renata
    Kovacs, Laszlo
    Weber, Lutz
    Takacs, Ferenc
    Hajdu, Istvan
    Fabo, Gabriella
    Cseh, Sandor
    Barna, Laszlo
    Csont, Tamas
    Csonka, Csaba
    Dorman, Gyoergy
    Ferdinandy, Peter
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [50] Control of matrix metalloproteinase-2 activity by phosphorylation
    Sariahmetoglu, M
    Leon, H
    Sawicka, J
    Sawicki, G
    Schulz, R
    FASEB JOURNAL, 2004, 18 (05): : A1115 - A1115